Somewhat Favorable Press Coverage Somewhat Unlikely to Affect HCA Healthcare (HCA) Share Price
Press coverage about HCA Healthcare (NYSE:HCA) has been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. HCA Healthcare earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.030867742124 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- Lazard Asset Management LLC Grows Holdings in HCA Healthcare Inc (HCA) (americanbankingnews.com)
- Corient Capital Partners LLC Boosts Stake in HCA Healthcare Inc (HCA) (americanbankingnews.com)
- HCA Healthcare Inc (HCA) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- The less you take Risk the low you earn : HCA Healthcare, Inc. (HCA) – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Revenue Approximations Analysis: Vertex Pharmaceuticals Incorporated, (NASDAQ: VRTX), HCA Healthcare, Inc … – TNN (tradingnewsnow.com)
HCA has been the subject of a number of recent analyst reports. Credit Suisse Group restated an “outperform” rating and issued a $25.00 price objective on shares of HCA Healthcare in a research note on Tuesday, December 26th. Robert W. Baird set a $104.00 price objective on HCA Healthcare and gave the company a “buy” rating in a research note on Friday, January 12th. Morgan Stanley downgraded HCA Healthcare from an “equal weight” rating to an “underweight” rating and set a $85.00 price objective for the company. in a research note on Wednesday, December 20th. Bank of America downgraded HCA Healthcare from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $94.00 to $90.00 in a research note on Thursday, January 4th. Finally, Goldman Sachs Group initiated coverage on HCA Healthcare in a research note on Wednesday, January 3rd. They issued a “neutral” rating for the company. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and eighteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $104.50.
HCA Healthcare (NYSE:HCA) last issued its quarterly earnings data on Tuesday, January 30th. The company reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.25. The business had revenue of $11.56 billion for the quarter, compared to analysts’ expectations of $11.19 billion. HCA Healthcare had a negative return on equity of 49.49% and a net margin of 4.89%. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.80 EPS. research analysts forecast that HCA Healthcare will post 8.71 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Thursday, March 1st will be issued a dividend of $0.35 per share. The ex-dividend date of this dividend is Wednesday, February 28th. This represents a $1.40 dividend on an annualized basis and a yield of 1.38%. HCA Healthcare’s dividend payout ratio (DPR) is 23.57%.
In related news, insider Charles J. Hall sold 49,882 shares of the stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $101.29, for a total transaction of $5,052,547.78. Following the sale, the insider now owns 62,048 shares of the company’s stock, valued at approximately $6,284,841.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael S. Cuffe sold 2,400 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $86.63, for a total value of $207,912.00. The disclosure for this sale can be found here. Insiders have sold a total of 482,318 shares of company stock worth $48,394,005 in the last three months. 2.90% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect HCA Healthcare (HCA) Share Price” was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-hca-healthcare-hca-share-price/1907802.html.
HCA Healthcare Company Profile
HCA Healthcare, Inc, formerly HCA Holdings, Inc, is a holding company. The Company, through its subsidiaries, owns and operates hospitals and related healthcare entities. As of December 31, 2016, the Company operated in two geographically organized groups, including the National and American Groups. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia.
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.